226 related articles for article (PubMed ID: 24302746)
1. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
2. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
3. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
van Lierop AH; Hamdy NA; van Egmond ME; Bakker E; Dikkers FG; Papapoulos SE
J Bone Miner Res; 2013 Apr; 28(4):848-54. PubMed ID: 23074140
[TBL] [Abstract][Full Text] [Related]
4. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
Wang N; Xue P; Wu X; Ma J; Wang Y; Li Y
Endocr Res; 2018 Feb; 43(1):29-38. PubMed ID: 28972408
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
6. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin and DKK1 in primary hyperparathyroidism.
Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
[TBL] [Abstract][Full Text] [Related]
8. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
9. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
11. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
[TBL] [Abstract][Full Text] [Related]
12. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
[TBL] [Abstract][Full Text] [Related]
13. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
[TBL] [Abstract][Full Text] [Related]
14. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
[TBL] [Abstract][Full Text] [Related]
15. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
[TBL] [Abstract][Full Text] [Related]
17. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
[TBL] [Abstract][Full Text] [Related]
18. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.
Yavropoulou MP; van Lierop AH; Hamdy NA; Rizzoli R; Papapoulos SE
Bone; 2012 Jul; 51(1):153-7. PubMed ID: 22579776
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin deficiency in humans.
van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
